E3泛素连接酶FBXW2与临床相关疾病的研究进展  

Research progress in E 3 ubiquitin ligase FBXW 2 and its clinical relevant diseases

作　　者：黄佳宇 熊安琪 蒋弼瀛 陈文佳[1] HUANG Jiayu;XIONG Anqi;JIANG Biying;CHEN Wenjia(Department of Cardiology,First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院心内科,哈尔滨150001

出　　处：《临床与病理杂志》2024年第12期1681-1686,共6页Journal of Clinical and Pathological Research

基　　金：黑龙江省博士后科研启动基金(LBH-Q20109);哈尔滨医科大学研究生科研和实践创新项目(YJSCX2023-192HYD)。

摘　　要：FBXW2作为F-box和WD重复结构域(F-box and WD repeat domaining,FBXW)家族成员之一,是SCF(Skp1-Cullin1-F-box)型E3泛素连接酶的重要组成部分,其分子特征与生物学功能近年来受到广泛关注。作为一种E3泛素连接酶,FBXW2可参与调节多种蛋白质的水平,在细胞周期进程、基因组稳定性维持及细胞命运决定中发挥重要作用,并且与多种疾病发生和治疗密切相关,如FBXW2可以作为肿瘤抑制因子抑制肺癌、乳腺癌和前列腺癌等多种癌症的发展,FBXW2可作为巨噬细胞中的炎症介质参与动脉粥样硬化的形成和胰岛素抵抗相关的肥胖发生。此外,FBXW2还与骨膜成骨相关。对FBXW2的生理机制及其在肺癌、乳腺癌、动脉粥样硬化等多种疾病中的生理病理机制进行详细综述,可为进一步研究FBXW2的作用提供依据。FBXW2,a member of the F-box and WD repeat domaining(FBXW)protein family,is an important component of the Skp1-Cullin1-F-box(SCF)E3 ubiquitin ligase complex.In recent years,its molecular characteristics and biological functions have attracted increasing attention.As an E3 ubiquitin ligase,FBXW2 participates in the regulation of various protein levels,playing crucial roles in cell cycle progression,maintenance of genomic stability,and determination of cell fate,It is closely associated with the development and treatment of numerous diseases.For instance,FBXW2 can function as a tumor suppressor,inhibiting the progression of various cancers such as lung cancer,breast cancer,and prostate cancer.Additionally,FBXW2 acts as an inflammatory mediator in macrophages and is involved in the formation of atherosclerosis and insulin resistance-related obesity.FBXW2 is also implicated in periosteal osteogenesis.This review provides a detailed summary of the physiological mechanisms of FBXW2 and its pathophysiological roles in diseases such as lung cancer,breast cancer,and atherosclerosis,aiming to offer a foundation for future research of FBXW2.

关 键 词：FBXW2 泛素-蛋白酶体系统 E3泛素连接酶 癌症 动脉粥样硬化 

分 类 号：R363[医药卫生—病理学]